Sectors
ERNA
Ernexa Therapeutics Inc.
4.68
2 x 3.40
2 x 5.97
bid
ask
+
0.11
2.41%
10:10 AM
timesize
| Ytd | -84.40% | |
| 1y | -85.92% |
4.68
day range
4.68
3.18
52 week range
71.50
| Open | 4.68 | Prev Close | 4.57 | Low | 4.68 | High | 4.68 | Mkt Cap | 5.46M |
| Vol | 467.00 | Avg Vol | 472.93K | EPS | -0.41 | P/E | N/A | Forward P/E | -0.03 |
| Beta | 2.57 | Short Ratio | 1.07 | Inst. Own | 11.00% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 5.13 | 200-d Avg | 13.92 | 1yr Est | 3.00 |
| Income Statement | |||
| Operating Expenses | 4.10M | ||
| Research and Development Expense | 2.79M | ||
| Selling, General and Administrative Expense | 1.31M | ||
| Operating Income | -4.10M | ||
| Interest Expense | 55.00K | ||
| Net Income | -4.01M | ||
| Net Income Common Stock | -4.02M | ||
| Net Income Common Stock (USD) | -4.02M | ||
| Consolidated Income | -4.01M | ||
| Earnings per Basic Share | -3.40 | ||
| Earnings per Basic Share (USD) | -3.40 | ||
| Earnings per Diluted Share | -3.40 | ||
| Earning Before Interest & Taxes (EBIT) | -3.95M | ||
| Earning Before Interest & Taxes (USD) | -3.95M | ||
| Preferred Dividends Income Statement Impact | 8.00K | ||
| Weighted Average Shares | 1.18M | ||
| Weighted Average Shares Diluted | 1.18M | ||
| Balance Sheet | |||
| Cash and Equivalents | 5.03M | ||
| Cash and Equivalents (USD) | 5.03M | ||
| Trade and Non-Trade Receivables | 83.00K | ||
| Current Assets | 5.89M | ||
| Property, Plant & Equipment Net | 396.00K | ||
| Total Assets | 6.32M | ||
| Debt Current | 167.00K | ||
| Total Debt | 349.00K | ||
| Current Liabilities | 2.93M | ||
| Debt Non-Current | 182.00K | ||
| Total Liabilities | 3.12M | ||
| Accumulated Retained Earnings (Deficit) | -255.16M | ||
| Shareholders Equity | 3.20M | ||
| Shareholders Equity (USD) | 3.20M | ||
| Assets Non-Current | 421.00K | ||
| Total Debt (USD) | 349.00K | ||
| Liabilities Non-Current | 183.00K | ||
| Trade and Non-Trade Payables | 1.63M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 44.00K | ||
| Net Cash Flow from Financing | 6.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.15M | ||
| Capital Expenditure | -3.00K | ||
| Issuance (Purchase) of Equity Shares | 6.00K | ||
| Net Cash Flow from Investing | -3.00K | ||
| Net Cash Flow from Operations | -4.15M | ||
| Share Based Compensation | 320.00K | ||